Covered recipient · General Payments record
SAAKSHI KHATTRI
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$371,070.07
438 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $230,722.00 | 93 |
| Consulting Fee | $94,729.37 | 38 |
| Travel and Lodging | $37,775.78 | 120 |
| Food and Beverage | $7,842.92 | 187 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $146,678.95 | 195 |
| Janssen Scientific Affairs, LLC | $70,404.90 | 55 |
| Lilly USA, LLC | $45,873.97 | 42 |
| UCB, Inc. | $24,816.10 | 21 |
| Regeneron Healthcare Solutions, Inc. | $20,280.71 | 23 |
| Janssen Biotech, Inc. | $18,069.91 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15,322.79 | 11 |
| LEO Pharma Inc. | $14,793.90 | 28 |
| Novartis Pharmaceuticals Corporation | $5,366.51 | 11 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $3,450.00 | 1 |
| Dermavant Sciences, Inc. | $2,175.18 | 2 |
| Eli Lilly and Company | $1,250.00 | 2 |
| E.R. Squibb & Sons, L.L.C. | $1,245.62 | 7 |
| GENZYME CORPORATION | $1,228.28 | 3 |
| Incyte Corporation | $27.59 | 2 |
| Regeneron Pharmaceuticals, Inc. | $22.85 | 1 |
| Galderma Laboratories, L.P. | $17.96 | 1 |
| Genentech USA, Inc. | $17.30 | 1 |
| Sun Pharmaceutical Industries Inc. | $15.04 | 1 |
| PFIZER INC. | $12.51 | 2 |
Page 5 of 9; records 201–250 of 438 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
SAAKSHI KHATTRI
NPI 1265677033 · CMS profile ID 1304956
Allopathic & Osteopathic Physicians / Dermatology
NEW YORK, NY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 5 of 9; records 201–250 of 438 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1265677033?year=2022&recipient=provider&page=5#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- SAAKSHI KHATTRI, NPI 1265677033, CMS profile ID 1304956. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 9; records 201–250 of 438 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265677033?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). SAAKSHI KHATTRI, NPI 1265677033, CMS profile ID 1304956. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 9; records 201–250 of 438 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265677033?year=2022&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- SAAKSHI KHATTRI, NPI 1265677033, CMS profile ID 1304956, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 9; records 201–250 of 438 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1265677033?year=2022&recipient=provider&page=5#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
438 matching records · $371,070.07 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 201–250 of 438.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| LEO Pharma Inc. | $273.60 | 07/21/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 936237021 | CMS |
| LEO Pharma Inc. | $178.00 | 07/21/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 936237027 | CMS |
| ABBVIE INC. | $575.00 | 07/18/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061151 | CMS |
| UCB, Inc. | $1,420.00 | 07/06/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1038609277 | CMS |
| ABBVIE INC. | $1,725.00 | 07/05/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061149 | CMS |
| ABBVIE INC. | $20.66 | 06/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061147 | CMS |
| Lilly USA, LLC | $3,125.00 | 06/30/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918318831 | CMS |
| ABBVIE INC. | $28.56 | 06/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061145 | CMS |
| ABBVIE INC. | $1,725.00 | 06/21/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061139 | CMS |
| ABBVIE INC. | $2,875.00 | 06/21/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061141 | CMS |
| ABBVIE INC. | $6.72 | 06/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061143 | CMS |
| Lilly USA, LLC | $2,200.00 | 06/21/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918296891 | CMS |
| Lilly USA, LLC | $2,500.00 | 06/21/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918339329 | CMS |
| Janssen Scientific Affairs, LLC | $1,250.00 | 06/18/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887240161 | CMS |
| ABBVIE INC. | $118.77 | 06/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061135 | CMS |
| ABBVIE INC. | $497.78 | 06/16/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061137 | CMS |
| Lilly USA, LLC | $231.59 | 06/15/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918280249 | CMS |
| Lilly USA, LLC | $142.56 | 06/15/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918295429 | CMS |
| Lilly USA, LLC | $181.55 | 06/15/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918296887 | CMS |
| Lilly USA, LLC | $122.26 | 06/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918318819 | CMS |
| Lilly USA, LLC | $193.08 | 06/15/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918326243 | CMS |
| Lilly USA, LLC | $143.23 | 06/15/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918339325 | CMS |
| Lilly USA, LLC | $498.18 | 06/15/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918361801 | CMS |
| ABBVIE INC. | $61.68 | 06/13/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061131 | CMS |
| ABBVIE INC. | $5,175.00 | 06/13/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061133 | CMS |
| Janssen Biotech, Inc. | $35.22 | 06/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886276675 | CMS |
| Lilly USA, LLC | $1,250.00 | 06/13/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918326247 | CMS |
| ABBVIE INC. | $160.55 | 06/08/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061127 | CMS |
| ABBVIE INC. | $1,725.00 | 06/08/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061129 | CMS |
| ABBVIE INC. | $2,875.00 | 06/07/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061125 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $93.53 | 06/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887784941 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $487.81 | 06/07/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887784955 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $186.45 | 06/07/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887784957 | CMS |
| Janssen Scientific Affairs, LLC | $71.26 | 06/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887240175 | CMS |
| ABBVIE INC. | $185.60 | 06/03/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061121 | CMS |
| ABBVIE INC. | $35.14 | 06/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061123 | CMS |
| ABBVIE INC. | $124.54 | 06/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061117 | CMS |
| ABBVIE INC. | $677.30 | 06/02/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061119 | CMS |
| Janssen Scientific Affairs, LLC | $2,813.00 | 05/28/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887240167 | CMS |
| Janssen Scientific Affairs, LLC | $4,375.00 | 05/28/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887240199 | CMS |
| Lilly USA, LLC | $1,250.00 | 05/27/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918295433 | CMS |
| ABBVIE INC. | $3.96 | 05/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061115 | CMS |
| Janssen Scientific Affairs, LLC | $117.87 | 05/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887240183 | CMS |
| Janssen Scientific Affairs, LLC | $2,550.88 | 05/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 887240191 | CMS |
| ABBVIE INC. | $71.77 | 05/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061105 | CMS |
| ABBVIE INC. | $191.35 | 05/24/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061107 | CMS |
| ABBVIE INC. | $1,725.00 | 05/24/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061109 | CMS |
| ABBVIE INC. | $1,725.00 | 05/24/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061111 | CMS |
| ABBVIE INC. | $1,725.00 | 05/24/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061113 | CMS |
| ABBVIE INC. | $26.13 | 05/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893061103 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $451,392.98 | 155 |
| PY2024 | Principal investigator | $9,724,584.84 | 263 |
| PY2023 | Recipient | $3,200.00 | 1 |
| PY2023 | Principal investigator | $1,915,390.66 | 56 |
| PY2022 | Recipient | $17,686.85 | 2 |
| PY2022 | Principal investigator | $332,040.88 | 24 |
| PY2021 | Principal investigator | $390,424.71 | 28 |
| PY2020 | Recipient | $5,200.00 | 1 |
| PY2020 | Principal investigator | $116,617.20 | 16 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
155 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Incyte Corporation | $1,484.10 | 12/19/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib | No dispute reported | 06/30/2026 | 1240477409 |
| Principal investigator 1 | Incyte Corporation | $6,846.60 | 12/08/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560508 |
| Principal investigator 1 | Incyte Corporation | $52.14 | 12/01/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477414 |
| Principal investigator 1 | Incyte Corporation | $35.55 | 12/01/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477430 |
| Principal investigator 1 | Incyte Corporation | $1.02 | 12/01/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477435 |
| Principal investigator 1 | Incyte Corporation | $14.22 | 12/01/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477439 |
| Principal investigator 1 | Incyte Corporation | $47.40 | 12/01/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477443 |
| Principal investigator 1 | Incyte Corporation | $47.40 | 12/01/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477447 |
| Principal investigator 1 | Incyte Corporation | $11.85 | 12/01/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477460 |
| Principal investigator 1 | Incyte Corporation | $11.85 | 12/01/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477464 |
| Principal investigator 1 | Incyte Corporation | $1,777.00 | 11/24/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560490 |
| Principal investigator 1 | Incyte Corporation | $1,256.90 | 11/24/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560503 |
| Principal investigator 1 | Incyte Corporation | $2,349.90 | 11/12/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560497 |
| Principal investigator 1 | Incyte Corporation | $20,250.00 | 11/07/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560476 |
| Principal investigator 1 | Incyte Corporation | $7,000.00 | 11/07/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560480 |
| Principal investigator 1 | Incyte Corporation | $114.50 | 11/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477419 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 11/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477422 |
| Principal investigator 1 | Incyte Corporation | $54.76 | 11/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477427 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 11/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477455 |
| Principal investigator 1 | ABBVIE INC. | $8,348.00 | 10/21/2025 | Non-covered Recipient Entity ICAHN SCHOOL OF MED AT MT SINAI | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202517557 |
| Principal investigator 1 | ABBVIE INC. | $8,348.00 | 10/21/2025 | Non-covered Recipient Entity ICAHN SCHOOL OF MED AT MT SINAI | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | No dispute reported | 06/30/2026 | 1202517559 |
| Principal investigator 1 | Incyte Corporation | $1,777.00 | 10/20/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560486 |
| Principal investigator 1 | Incyte Corporation | $93.60 | 10/20/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560531 |
| Principal investigator 1 | Incyte Corporation | $2,489.00 | 10/20/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560539 |
| Principal investigator 1 | Incyte Corporation | $1,115.80 | 10/02/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560513 |
| Principal investigator 1 | Incyte Corporation | $1,594.00 | 10/02/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560518 |
| Principal investigator 1 | Incyte Corporation | $1,594.00 | 10/02/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560524 |
| Principal investigator 1 | Incyte Corporation | $109.52 | 10/01/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477451 |
| Principal investigator 1 | Incyte Corporation | $1,556.10 | 09/10/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560470 |
| Principal investigator 1 | Incyte Corporation | $1,157.60 | 08/20/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560428 |
| Principal investigator 1 | Incyte Corporation | $1,594.00 | 08/20/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560433 |
| Principal investigator 1 | Incyte Corporation | $2,823.00 | 08/20/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560465 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,202.20 | 08/15/2025 | Covered Recipient Teaching Hospital MOUNT SINAI HOSPITAL | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223268156 |
| Principal investigator 1 | Incyte Corporation | $1,295.00 | 08/01/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560438 |
| Principal investigator 1 | Incyte Corporation | $2,611.00 | 08/01/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560444 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $101.25 | 07/23/2025 | Covered Recipient Teaching Hospital MOUNT SINAI HOSPITAL | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223268152 |
| Principal investigator 1 | Incyte Corporation | $1,127.90 | 07/18/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560450 |
| Principal investigator 1 | Incyte Corporation | $2,489.00 | 07/18/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560455 |
| Principal investigator 1 | Incyte Corporation | $578.00 | 07/18/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560459 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,720.64 | 07/09/2025 | Covered Recipient Teaching Hospital MOUNT SINAI HOSPITAL | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223268150 |
| Principal investigator 1 | Incyte Corporation | $1,594.00 | 06/25/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560366 |
| Principal investigator 1 | Incyte Corporation | $1,777.00 | 06/25/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560373 |
| Principal investigator 1 | Incyte Corporation | $1,594.00 | 06/25/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560392 |
| Principal investigator 1 | Incyte Corporation | $1,743.60 | 06/25/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560400 |
| Principal investigator 1 | Incyte Corporation | $1,729.00 | 06/11/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560381 |
| Principal investigator 1 | Incyte Corporation | $2,611.00 | 06/11/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560387 |
| Principal investigator 1 | Incyte Corporation | $1,122.10 | 06/11/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560413 |
| Principal investigator 1 | Incyte Corporation | $6.18 | 06/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477302 |
| Principal investigator 1 | Incyte Corporation | $31.93 | 06/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477356 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 06/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477361 |
| Principal investigator 1 | Incyte Corporation | $64.72 | 06/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477365 |
| Principal investigator 1 | Incyte Corporation | $217.55 | 06/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477369 |
| Principal investigator 1 | Incyte Corporation | $8.48 | 06/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477382 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 06/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477386 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 06/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477390 |
| Principal investigator 1 | Incyte Corporation | $32.88 | 06/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477394 |
| Principal investigator 1 | Incyte Corporation | $2,240.10 | 05/21/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560417 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,432.85 | 05/21/2025 | Non-covered Recipient Entity ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223280070 |
| Principal investigator 1 | Incyte Corporation | $425.00 | 05/12/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560405 |
| Principal investigator 1 | Incyte Corporation | $750.00 | 05/12/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560410 |
| Principal investigator 1 | Incyte Corporation | $59.13 | 05/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477332 |
| Principal investigator 1 | Incyte Corporation | $19.44 | 05/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477336 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 05/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477341 |
| Principal investigator 1 | Incyte Corporation | $124.54 | 05/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477345 |
| Principal investigator 1 | Incyte Corporation | $80.90 | 05/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477353 |
| Principal investigator 1 | Incyte Corporation | $68.70 | 05/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477378 |
| Principal investigator 1 | Incyte Corporation | $1,594.00 | 05/02/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560344 |
| Principal investigator 1 | Incyte Corporation | $1,383.20 | 05/02/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560351 |
| Principal investigator 1 | Incyte Corporation | $1,439.90 | 05/02/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560359 |
| Principal investigator 1 | Incyte Corporation | $1,729.00 | 05/02/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560422 |
| Principal investigator 1 | Incyte Corporation | $1,295.00 | 04/09/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560318 |
| Principal investigator 1 | Incyte Corporation | $2,611.00 | 04/09/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560337 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,170.86 | 04/09/2025 | Non-covered Recipient Entity ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223277752 |
| Principal investigator 1 | Incyte Corporation | $34.35 | 04/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477306 |
| Principal investigator 1 | Incyte Corporation | $26.73 | 04/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477311 |
| Principal investigator 1 | Incyte Corporation | $31.93 | 04/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477316 |
| Principal investigator 1 | Incyte Corporation | $0.93 | 04/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477319 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 04/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477324 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 04/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477328 |
| Principal investigator 1 | Incyte Corporation | $74.04 | 04/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477349 |
| Principal investigator 1 | Incyte Corporation | $80.90 | 04/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477373 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 04/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477397 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 04/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477402 |
| Principal investigator 1 | Incyte Corporation | $24.66 | 04/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477406 |
| Principal investigator 1 | Incyte Corporation | $1,777.00 | 04/02/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560314 |
| Principal investigator 1 | Incyte Corporation | $578.00 | 04/02/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560325 |
| Principal investigator 1 | Incyte Corporation | $1,199.10 | 04/02/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560333 |
| Principal investigator 1 | Incyte Corporation | $2,611.00 | 03/12/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560222 |
| Principal investigator 1 | Incyte Corporation | $1,952.00 | 03/12/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560229 |
| Principal investigator 1 | Incyte Corporation | $748.60 | 03/12/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560251 |
| Principal investigator 1 | Incyte Corporation | $1,783.00 | 03/12/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560270 |
| Principal investigator 1 | Incyte Corporation | $1,109.90 | 03/12/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560295 |
| Principal investigator 1 | Incyte Corporation | $270.80 | 03/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477232 |
| Principal investigator 1 | Incyte Corporation | $240.45 | 03/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477257 |
| Principal investigator 1 | Incyte Corporation | $186.81 | 03/03/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477264 |
| Principal investigator 1 | Incyte Corporation | $1,777.00 | 03/03/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560234 |
| Principal investigator 1 | Incyte Corporation | $2,823.00 | 03/03/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560239 |
| Principal investigator 1 | Incyte Corporation | $1,011.60 | 03/03/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560244 |
| Principal investigator 1 | Incyte Corporation | $1,594.00 | 03/03/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560258 |
| Principal investigator 1 | Incyte Corporation | $1,777.00 | 03/03/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560288 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,791.94 | 03/03/2025 | Covered Recipient Teaching Hospital MOUNT SINAI HOSPITAL | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223268138 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,881.92 | 02/14/2025 | Non-covered Recipient Entity Mount Sinai School Of Medicine | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) | No dispute reported | 06/30/2026 | 1235995603 |
| Principal investigator 1 | Incyte Corporation | $1,729.00 | 02/10/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560207 |
| Principal investigator 1 | Incyte Corporation | $2,611.00 | 02/10/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560211 |
| Principal investigator 1 | Incyte Corporation | $1,851.00 | 02/10/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560217 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,030.93 | 02/03/2025 | Covered Recipient Teaching Hospital MOUNT SINAI HOSPITAL | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD | No dispute reported | 06/30/2026 | 1223268136 |
| Principal investigator 1 | AstraZeneca UK Limited | $86,061.16 | 01/27/2025 | Non-covered Recipient Entity ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | A Multicenter Randomized Double blind Placebo controlled Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus and Refractory and/or Intolerant to Antimalarial Therapy | No dispute reported | 06/30/2026 | 1185540850 |
| Principal investigator 1 | Incyte Corporation | $1,594.00 | 01/27/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560178 |
| Principal investigator 1 | Incyte Corporation | $1,777.00 | 01/27/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560180 |
| Principal investigator 1 | Incyte Corporation | $1,777.00 | 01/27/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560185 |
| Principal investigator 1 | Incyte Corporation | $578.00 | 01/27/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560264 |
| Principal investigator 1 | Incyte Corporation | $1,594.00 | 01/27/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560302 |
| Principal investigator 1 | Incyte Corporation | $286.70 | 01/15/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560140 |
| Principal investigator 1 | Incyte Corporation | $2,811.00 | 01/15/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560146 |
| Principal investigator 1 | Incyte Corporation | $1,862.00 | 01/15/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560152 |
| Principal investigator 1 | Incyte Corporation | $1,952.00 | 01/15/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560157 |
| Principal investigator 1 | Incyte Corporation | $2,611.00 | 01/15/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560162 |
| Principal investigator 1 | Incyte Corporation | $1,594.00 | 01/15/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560167 |
| Principal investigator 1 | Incyte Corporation | $578.00 | 01/15/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560173 |
| Principal investigator 1 | Incyte Corporation | $276.40 | 01/15/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560191 |
| Principal investigator 1 | Incyte Corporation | $1,777.00 | 01/15/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560200 |
| Principal investigator 1 | Incyte Corporation | $1,729.00 | 01/15/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560276 |
| Principal investigator 1 | Incyte Corporation | $1,729.00 | 01/15/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560282 |
| Principal investigator 1 | Incyte Corporation | $1,777.00 | 01/15/2025 | Non-covered Recipient Entity MOUNT SINAI DOCTORS | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240560306 |
| Principal investigator 1 | Amgen Inc. | $140,903.31 | 01/02/2025 | Non-covered Recipient Entity ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies | No dispute reported | 06/30/2026 | 1246642447 |
| Principal investigator 1 | Incyte Corporation | $79.50 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477162 |
| Principal investigator 1 | Incyte Corporation | $90.10 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477168 |
| Principal investigator 1 | Incyte Corporation | $121.90 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477172 |
| Principal investigator 1 | Incyte Corporation | $84.80 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477177 |
| Principal investigator 1 | Incyte Corporation | $206.70 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477181 |
| Principal investigator 1 | Incyte Corporation | $106.00 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477185 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477190 |
| Principal investigator 1 | Incyte Corporation | $95.40 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477194 |
| Principal investigator 1 | Incyte Corporation | $37.10 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477198 |
| Principal investigator 1 | Incyte Corporation | $32.28 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477202 |
| Principal investigator 1 | Incyte Corporation | $63.60 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477206 |
| Principal investigator 1 | Incyte Corporation | $53.00 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477211 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477215 |
| Principal investigator 1 | Incyte Corporation | $42.40 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477219 |
| Principal investigator 1 | Incyte Corporation | $74.20 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477221 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477224 |
| Principal investigator 1 | Incyte Corporation | $114.50 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477228 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477237 |
| Principal investigator 1 | Incyte Corporation | $16.14 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477240 |
| Principal investigator 1 | Incyte Corporation | $109.52 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477244 |
| Principal investigator 1 | Incyte Corporation | $26.90 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477248 |
| Principal investigator 1 | Incyte Corporation | $15.90 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477253 |
| Principal investigator 1 | Incyte Corporation | $124.54 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477261 |
| Principal investigator 1 | Incyte Corporation | $62.27 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477269 |
| Principal investigator 1 | Incyte Corporation | $201.40 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477274 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477281 |
| Principal investigator 1 | Incyte Corporation | $37.66 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477285 |
| Principal investigator 1 | Incyte Corporation | $21.52 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477290 |
| Principal investigator 1 | Incyte Corporation | $53.00 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477294 |
| Principal investigator 1 | Incyte Corporation | $53.00 | 01/02/2025 | Covered Recipient Teaching Hospital Mount Sinai Hospital | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa | No dispute reported | 06/30/2026 | 1240477298 |